Kidney Diseases, Cystic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Kidney Diseases, Cystic. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Kidney Diseases, Cystic receives a directional strategic score of 57/100, combining unmet need (69/100), competitive intensity (96/100, where higher means more competition) and market attractiveness (80/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

A heterogeneous group of hereditary and acquired disorders in which the KIDNEY contains one or more CYSTS unilaterally or bilaterally (KIDNEY, CYSTIC).

The reproducible entity is Patsnap disease ID 606448d05c7f43ad94c25dc136e2e019 with MeSH identifier D052177. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: USRDS 2024 Annual Data Report - Kidney Disease among Children and Adolescents

USRDS 2024 Annual Data Report - Kidney Disease among Children and Adolescents Chronic Kidney Disease: Chapter 5 Kidney Disease among Children and Adolescents What's New The International Classification of Diseases code list used to identify the presence of kidney disease in children was extensively reviewed through a consensus exercise involving pediatric nephrologists familiar with the epidemiology of kidney disease. Urologic and other conditions that were not accompanied or likely to be accompanied by kidney disease or dysfunction were removed from the list of CKD codes used for this chapter. Additionally, codes for cystic diseases, which have traditionally been part of CAKUT (congenital anomalies of the kidney and urologic tract), were grouped into a dedicated disease category, thereby allowing us to show five, rather than four, causes of kidney disease in children. This year, we report prevalence of eGFR <60 mL/min/1.73 m in NHANES using the U25 equation. 2 Highlights Structural disorders were the most common cause of kidney disease in children with Medicaid coverage, at 53.2% (Figure 5.1); glomerulonephritis (GN) was the cause in 18.8%. Among children insured with Medicaid in 2022, those with kidney disease were 15 times as likely to be hospitalized as those without kidney disease (Figure 5.2). Overall, children insured with Medicaid in 2022 with kidney disease were 20 times as likely to be hospitalized for an infectious cause (including COVID-19) than those without kidney disease (Figure 5.3a). Overall, children insured with Medicaid in 2022 with kidney disease were 1

Review the epidemiology source

Epidemiology evidence 2: USRDS 2021 Annual Data Report - Incidence, Prevalence, Patient Characteristics, and Treatment Modalities Incidence, Prevalence, Patient Characteristics, and Treatment

USRDS 2021 Annual Data Report - Incidence, Prevalence, Patient Characteristics, and Treatment Modalities End Stage Renal Disease: Chapter 1 Incidence, Prevalence, Patient Characteristics, and Treatment Modalities Highlights In 2019, 134,608 individuals were newly diagnosed with end-stage renal disease (ESRD), representing an increase of 2.7% from the previous year and 15.8% from a decade ago (Figure 1.1). However, the adjusted incidence fell from a peak of 431 per million population (pmp) in 2006 to 386 pmp in 2019. In 2019, 85% of those with incident ESRD initiated in-center hemodialysis (HD) (Figure 1.2). This represents a decrease from 91% in 2009. Over the past decade, the percentage initiating kidney replacement therapy with peritoneal dialysis (PD) nearly doubled, from 6% to 11%. The percentage who received a preemptive kidney transplant remained unchanged over the decade at about 3%. Adjusted ESRD incidence increased as age increased: among individuals aged 0-17 years, the adjusted incidence in 2019 was 12 pmp; among individuals aged 65-74 years, 1,307 pmp; and among individuals aged ≥75 years 1,587 pmp (Figure 1.4). Between 2009 and 2019, adjusted ESRD incidence in Black individuals decreased by 17.5%, in Native American individuals by 14.1%, in Hispanic individuals by 12.1%, in Asian individuals by 5.2%, and in White individuals by 2.4% (Figure 1.4). However, in all individuals except for Whites, adjusted incidence increased between 2018 and 2019. The prevalent count of individuals with ESRD reached 809,103 in 2019, an increase of 41.0% from 2009 (Figure 1.5). Adju

Review the epidemiology source

Epidemiology evidence 3: Heart Disease and Stroke Statistics—2023 Update Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

A, Incidence by sex. B, Incidence by race and ethnicity. Incidence estimates are presented as cases per million people and are adjusted for age, sex, race, and ethnicity. ESRD indicates end-stage renal disease. Source: Reprinted from 2021 United States Renal Data System Annual Data Report, volume 2, Figure 1.4.10 Chart 12-3. Use of home dialysis among prevalent cases, 2009 to 2019. Chart 12-3. This chart shows that the percent of patients using home dialysis increased steadily between 2009 and 2019, with approximately 13 percent of prevalent cases using home dialysis in 2019. Source: Reprinted from 2021 United States Renal Data System Annual Data Report, volume 2, Figure 2.1a.10 Chart 12-5. Prevalence of CKD, overall and by CKD category, among Medicare beneficiaries ≥66 years of age, United States, 1999 to 2018. Chart 12-5. This chart shows the prevalence of chronic kidney disease overall and by chronic kidney disease category among Medicare beneficiaries 66 years of age and older in the United States between 1999 and 2018. Over time, the prevalence of all codes, stage 2 and stage 3 is increasing. CKD indicates chronic kidney disease. y Source: Reprinted from 2020 United States Renal Data System Annual Data Report, volume 1, Figure 2.1.1 Chart 12-6. Prevalence of reduced eGFR and ACR in NHANES, United States, 2003 to 2018. Chart 12-6A. This chart shows fluctuation between 2003 to 2006 and 2015 to 2018 in the prevalence of eGFR stages in individuals with chronic kidney disease. The highest percentage of individuals occurs in stage 3 at all 3-year time points, followed by sta

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Kidney Diseases, Cystic, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Kidney Diseases, Cystic thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: NCC

Electroneutral sodium and chloride ion cotransporter, which acts as a key mediator of sodium and chloride reabsorption in kidney distal convoluted tubules (PubMed:18270262, PubMed:21613606, PubMed:22009145, PubMed:36351028, PubMed:36792826). Also acts as a receptor for the pro-inflammatory cytokine IL18, thereby contributing to IL18-induced cytokine production, including IFNG, IL6, IL18 and CCL2 (By similarity). May act either independently of IL18R1, or in a complex with IL18R1 (By similarity).

The mechanism anchor is SLC12A3. It is a pathway hypothesis, not a claim that every Kidney Diseases, Cystic patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 415 registered studies. Recent sampled records include:

• NCT07745920 — Managing Depressive Symptoms in ADPKD; Recruiting; Not Applicable; sponsor Mayo Clinic; enrollment 105.
• ChiCTR2600127298 — Efficacy and Safety of Retroperitoneoscopic - assisted Lower Thoracic Paravertebral Block for Postoperative Analgesia in Nephrectomy; Not yet recruiting; Not Applicable; sponsor not stated; enrollment 28.
• ACTRN12626000762358 — A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of GV-100 (Part 1 & Part 2); Recruiting; Phase 1; sponsor Novotech (Australia) Pty Ltd.; enrollment 56.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering, broader transaction labels or asset-level indexing. Add target- and asset-based comparable searches before valuation.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate SLC12A3 relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Kidney Diseases, Cystic merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if SLC12A3 modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Kidney Diseases, Cystic is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.